The key to TH-302's ultimate success is in combination - TH-302 attacks the hypoxic regions of the tumor and traditional chemo agents are designed to attack the rest. The issue that they are facing in the current combo trials is that, like most cancer trials, you have to start with the patients that are the sickest - i.e. the ones that have failed the current "standard of care" treatments. So, if conventional chemo agents have failed on these patients to date, there is nothing TH-302 is going to do to change that. Ultimately, these initial combo trials are designed to ensure safety in combination, so that they can then move toward using them in combo on first-line patients, where the traditional chemo agents should work for the majority of patients. When you get into these trials, the hope is that 1+1=3 (i.e. TH-302 + standard chemo = substantially higher cure rates or survival times).